menu
    • menu

    Company profile for Curatis

    NEW Drugs in Dev: 5
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Curatis, a specialty pharmaceutical company headquartered in Switzerland, specializes in acquiring, licensing, distributing, and promoting medications for the treatment and prevention of orphan and specialty diseases within Switzerland. These medicines are developed and introduced to the market by third-party pharmaceutical firms. With exclusive distribution rights for over 30 different drugs in Switzerland, many of which are ...
    Curatis, a specialty pharmaceutical company headquartered in Switzerland, specializes in acquiring, licensing, distributing, and promoting medications for the treatment and prevention of orphan and specialty diseases within Switzerland. These medicines are developed and introduced to the market by third-party pharmaceutical firms. With exclusive distribution rights for over 30 different drugs in Switzerland, many of which are targeted towards orphan and specialty diseases, Curatis solidifies its prominent position within the Swiss orphan drug market.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CuratisSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Weierweg 7 CH-4410 Liestal
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://curatis.com/
    Linkedin
    Linkedin
    https://ch.linkedin.com/company/curatis
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curatis Reports Strong FY25 Growth, Corticorelin Milestones
    Curatis Reports Strong FY25 Growth, Corticorelin Milestones

    24 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260323525062/en/Curatis-Double-Digit-Revenue-Growth-in-2025-and-Major-Milestones-for-Corticorelin-Achieved

    BUSINESSWIRE
    24 Mar 2026
    Share Share
    Curatis, Neupharma Sign Licensing Deal for Corticorelin
    Curatis, Neupharma Sign Licensing Deal for Corticorelin

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/curatis-and-neupharma-announce-exclusive-licensing-agreement-to-develop-and-market-corticorelin-c-p

    PHARMIWEB
    11 Mar 2026
    Share Share
    FDA Confirms Positive Outcome; Corticorelin on Track for Ph 3
    FDA Confirms Positive Outcome; Corticorelin on Track for Ph 3

    18 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250917939293/en/Curatis-FDA-Minutes-Confirm-Positive-Outcome-of-Meeting-on-9.-September-2025-Corticorelin-on-Track-for-Phase-3

    BUSINESSWIRE
    18 Sep 2025
    Share Share
    FDA Confirms Corticorelin Advancement to Phase 3
    FDA Confirms Corticorelin Advancement to Phase 3

    18 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-18/fda-minutes-confirm-positive-outcome-of-meeting-on-9-september-2025-corticorelin-on-track-for-pha

    PHARMAWEB
    18 Sep 2025
    Share Share
    Curatis Achieves Development Milestone for C-PTBE-01 Amid Growth
    Curatis Achieves Development Milestone for C-PTBE-01 Amid Growth

    15 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250914049177/en/Curatis-Double-Digit-Growth-in-Core-Business-and-Development-Milestone-Achieved-for-C-PTBE-01

    BUSINESSWIRE
    15 Sep 2025
    Share Share
    Curatis Expands Distribution with Phoenix Labs
    Curatis Expands Distribution with Phoenix Labs

    05 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-05/curatis-expands-distribution-business-with-phoenix-labs-with-up-to-chf-5m-additional-annual-revenues

    PHARMAWEB
    05 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search